Who are Placebo plus S1's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): oral administration of S-1, Capecitabine tablets, XELODA [capecitabine], Capecitabine (Xeloda®), Capecitabine-based chemotherapy, Ibandronate, Capecitabine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-plus-s1.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Placebo plus S1 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo plus S1 (Placebo plus S1) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fluoropyrimidine antimetabolite. Area: Oncology.

marketed Fluoropyrimidine antimetabolite Thymidylate synthase, dihydropyrimidine dehydrogenase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Placebo plus S1 (Placebo plus S1) — Chinese PLA General Hospital. S1 is a combination chemotherapy agent that inhibits thymidylate synthase and dihydropyrimidine dehydrogenase to disrupt DNA synthesis and cell division.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Placebo plus S1 TARGET	Placebo plus S1	Chinese PLA General Hospital	marketed	Fluoropyrimidine antimetabolite	Thymidylate synthase, dihydropyrimidine dehydrogenase
oral administration of S-1	oral administration of S-1	Japan Clinical Oncology Group	phase 3	Fluoropyrimidine antimetabolite	Thymidylate synthase, dihydropyrimidine dehydrogenase
Capecitabine tablets	Capecitabine tablets	UNICANCER	marketed	Fluoropyrimidine antimetabolite	Thymidylate synthase
XELODA [capecitabine]	XELODA [capecitabine]	Hoffmann-La Roche	marketed	Fluoropyrimidine antimetabolite	Thymidylate synthase
Capecitabine (Xeloda®)	Capecitabine (Xeloda®)	National Cancer Center, Korea	marketed	Fluoropyrimidine antimetabolite	Thymidylate synthase
Capecitabine-based chemotherapy	Capecitabine-based chemotherapy	Ain Shams University	phase 3	Fluoropyrimidine antimetabolite	Thymidylate synthase
Ibandronate, Capecitabine	Ibandronate, Capecitabine	GBG Forschungs GmbH	phase 3	Bisphosphonate + Fluoropyrimidine antimetabolite	Farnesyl pyrophosphate synthase (ibandronate); Thymidylate synthase (capecitabine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fluoropyrimidine antimetabolite class)

Federation Francophone de Cancerologie Digestive · 2 drugs in this class
National Cancer Center, Korea · 2 drugs in this class
Hoffmann-La Roche · 1 drug in this class
Japan Clinical Oncology Group · 1 drug in this class
Jiangxi Provincial Cancer Hospital · 1 drug in this class
Peter MacCallum Cancer Centre, Australia · 1 drug in this class
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · 1 drug in this class
Taiho Pharmaceutical Co., Ltd. · 1 drug in this class
The First Affiliated Hospital of Henan University of Science and Technology · 1 drug in this class
UNICANCER · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo plus S1 — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-plus-s1. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing